Prostate Cancer: Quo Vadis?

Eur Urol. 2019 Dec;76(6):709-711. doi: 10.1016/j.eururo.2019.06.031. Epub 2019 Jul 9.

Authors

Christopher J Logothetis¹, Ana Aparicio², Filippos Koinis³, Paul G Corn², Eleni Efstathiou²

Affiliations

¹ Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: clogothe@mdanderson.org.
² Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ School of Medicine, University of Thessaly, Larissa, Greece.

PMID: 31300238
DOI: 10.1016/j.eururo.2019.06.031

Abstract

Utility measures are urgently needed for clinical application of new, more sensitive diagnostics to reduce the risk of excessive intervention.

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Publication types

Editorial

MeSH terms

Humans
Male
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / therapy